Celebrate with us
More than 25 years in delivering a specialised, streamlined sales process, expert customer support and top quality service! Our core values include continuity and loyalty towards the people we work with: not only customers and suppliers but also to our employees and business partners.
Together we have been Delivering Life Sciences to the World for more than 25 years.
Collaboration with CalibreScientific
We are happy to announce our collaboration with Calibre Scientific, a company with headquarters in Los Angeles, California, representing a diverse portfolio of niche life sciences companies in the fields cell & molecular biology, proteomics, applied science & diagnostics.
Gyros Protein Technologies introduces next generation Gyrolab Protein A Kit for Biotherapeutics
Kit increases efficiency of residual protein A ligand detection
Uppsala, Sweden, May 10 , 2017: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, today announced it has launched a new version of its Gyrolab™ Protein A Kit.
Gyros Protein Technologies introduces a multi-species kit for pharmacokinetic studies
New kit for early-stage biotherapeutic development, optimized for use in Gyrolab™ systems
Uppsala, Sweden, 05 April 2017: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, announced today it has introduced a new kit for early-stage biotherapeutic pharmacokinetic (PK) studies.
Gyros: Finding the best platform for fit-for-purpose ADA assays
Gyrolab system delivers
Determining the immunogenic potential of a therapeutic antibody is a regulatory requirement during clinical development since anti-drug antibodies (ADA) can cause undesirable effects, ranging from loss of drug exposure and efficacy to serious adverse events. Justine Brose and her colleagues at Novimmune SA, Geneva, Switzerland evaluated four platforms to determine which platform and sample pre-treatment procedures could deliver a fit-for-purpose assay for ADA analysis to determine the immunogenicity of the therapeutic antibody Novimab. Of the platforms tested (ELISA and Gyrolab, Meso Scale Discovery, and AlphaLISA platforms) only Gyrolab and MSD platforms met all of their pre-specified assay requirements.